Stockscreener 앱 받기
25.45
0.43%
-0.11
전일 마감가:
$25.56
열려 있는:
$25.4
하루 거래량:
2,268
Relative Volume:
0.36
시가총액:
$N/A
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-0.16%
1개월 성능:
+0.20%
6개월 성능:
+0.43%
1년 성능:
-0.59%
1일 변동 폭
$25.40
$25.59
1주일 범위
$25.00
$25.63
52주 변동 폭
$23.32
$25.76
Xoma Corporation Stock (XOMAO) Company Profile
명칭
Xoma Corporation
전화
510 204 7200
주소
2200 Powell Street, Suite 310, EmeryVille
XOMAO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
XOMAO
Xoma Corporation
|
25.45 | 0 | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.38 | 114.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
748.71 | 78.80B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
396.04 | 51.80B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
847.05 | 53.08B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
166.55 | 42.33B | 447.02M | -1.18B | -906.14M | -6.1812 |
Xoma Corporation 주식(XOMAO)의 최신 뉴스
Short Squeeze: Will XOMA Royalty Corporation(X0M) stock rise with strong economyJuly 2025 Rallies & Free Accurate Trade Setup Notifications - DonanımHaber
Can XOMA Royalty Corporation stock outperform in 2025 bull marketQuarterly Performance Summary & AI Forecasted Entry and Exit Points - DonanımHaber
Can XOMA Royalty Corporation(X0M) stock sustain institutional flowsWeekly Trade Summary & Fast Moving Market Watchlists - DonanımHaber
Can XOMA Royalty Corporation stock double in next 5 yearsWeekly Trade Review & Free Risk Controlled Daily Trade Plans - Улправда
Will XOMA Royalty Corporation (X0M1) stock profit from fiscal stimulusM&A Rumor & Risk Adjusted Buy and Sell Alerts - Улправда
Jefferies downgrades Generation Bio stock to Hold as XOMA acquisition announced By Investing.com - Investing.com South Africa
Generation Bio is latest Mass. biotech to be acquired by Xoma - The Business Journals
XOMA to buy struggling Generation Bio - The Pharma Letter
Jefferies downgrades Generation Bio stock to Hold as XOMA acquisition announced - Investing.com Nigeria
‘Zombie’ biotech buyer Xoma to acquire Generation Bio - Yahoo Finance
XOMA Strikes Deal To Acquire Generation Bio, Expanding Royalty Portfolio - Nasdaq
XOMA Royalty to Acquire Generation Bio - citybiz
Generation Bio Announces Merger with XOMA Royalty - TipRanks
Xoma Royalty enters into agreement to acquire Generation Bio - marketscreener.com
XOMA Royalty Corporation to Acquire Generation Bio Co. in Cash Transaction with Milestone and Royalty Opportunities - Quiver Quantitative
Generation Bio (NASDAQ: GBIO) agrees to $4.29 sale to XOMA Royalty plus CVR - Stock Titan
Investors Don't See Light At End Of XOMA Royalty Corporation's (NASDAQ:XOMA) Tunnel - simplywall.st
Generation Bio (GBIO) to be acquired in planned XOMA tender offer - Stock Titan
FY2025 EPS Estimates for XOMA Royalty Reduced by Analyst - MarketBeat
XOMA Royalty Corporation: A Deep Dive into a Biotech Royalty Aggregator (12/13/2025) - Markets Financial Content
BVF Inc. IL Has $65.28 Million Stock Position in XOMA Royalty Corporation $XOMA - MarketBeat
Why (XOMAO) Price Action Is Critical for Tactical Trading - news.stocktradersdaily.com
Price-Driven Insight from (XOMA) for Rule-Based Strategy - news.stocktradersdaily.com
XOMA stock maintains Buy rating at Benchmark despite partner’s trial setback - Investing.com
XOMA: HC Wainwright Maintains Buy Rating, Lowers Price Target to $97 | XOMA Stock News - GuruFocus
Leerink Partners lowers XOMA stock price target on RZ358 trial failure By Investing.com - Investing.com South Africa
HC Wainwright & Co. Maintains XOMA Royalty (XOMA) Buy Recommendation - Nasdaq
HC Wainwright & Co. Maintains XOMA Royalty CorporationPreferred Stock (XOMAP) Buy Recommendation - Nasdaq
Why two Bay Area companies' stocks tumbled on a drug's clinical failure - The Business Journals
XOMA stock price target lowered to $97 by H.C. Wainwright - Investing.com Australia
XOMA Royalty Corporation (NASDAQ:XOMA) Receives Average Rating of "Hold" from Brokerages - MarketBeat
XOMA: Leerink Partners Lowers Price Target, Reiterates Outperfor - GuruFocus
Why Is XOMA Royalty Stock Sinking Thursday? - Benzinga
Leerink Partners lowers XOMA stock price target on RZ358 trial failure - Investing.com
LUCID CAPITAL MARKETS Initiates Coverage of XOMA Royalty CorporationPreferred Stock (XOMAP) with Buy Recommendation - Nasdaq
LUCID CAPITAL MARKETS Initiates Coverage of XOMA Royalty (XOMA) with Buy Recommendation - Nasdaq
Lucid Capital Markets initiates coverage on XOMA stock with Buy rating - Investing.com Canada
XOMA Royalty (XOMA): New Buy Rating Initiated by Lucid Capital M - GuruFocus
Xoma initiated with a Buy at Lucid Capital - TipRanks
CEO’s Bold Move: Massive Investment in Xoma Stock! - TipRanks
Insider Buying: XOMA Royalty (NASDAQ:XOMA) CEO Acquires 100,000 Shares of Stock - MarketBeat
XOMA Royalty Corp CEO Owen Hughes Acquires 100,000 Depositary Shares - TradingView
Xoma Royalty Expands Portfolio Through Mural Oncology Acquisition - AD HOC NEWS
XOMA Royalty completes acquisition of Mural Oncology for $2.035 per share - Investing.com Nigeria
XOMA Royalty completes acquisition of Mural Oncology By Investing.com - Investing.com Nigeria
Xoma Completes Acquisition of Mural Oncology - TipRanks
Xoma announces closing of transaction to acquire Mural Oncology - TipRanks
XOMA Royalty completes acquisition of Mural Oncology for $2.035 per share By Investing.com - Investing.com South Africa
Mural Oncology Announces Effectiveness of Scheme of Arrangement and Completion of Acquisition - Research Tree
Xoma Royalty announces closing of transaction to acquire Mural Oncology plc - marketscreener.com
XOMA Royalty Corporation Completes Acquisition of Mural Oncology plc Under Irish High Court Sanctioned Scheme - Quiver Quantitative
Xoma Corporation (XOMAO) 재무 분석
Xoma Corporation (XOMAO)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.31%
0.33%
자본화:
|
볼륨(24시간):